A Double-Blind Efficacy and Safety Study of Duloxetine Flexible Dosing in Children and Adolescents with Major Depressive Disorder
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The purpose of this study was to evaluate the efficacy and safety of duloxetine flexible dose in children (7-11 years) and adolescents (12-17 years) with major depressive disorder (MDD). METHODS: Patients (n=337) in this 36 week study (10 week acute and 26 week extension treatment) received duloxetine (60-120 mg once daily [QD], n=117), fluoxetine (20-40 mg QD, n=117), or placebo (n=103). Measures included: Children's Depression Rating Scale-Revised (CDRS-R), treatment-emergent adverse events (TEAEs), and Columbia-Suicide Severity Rating Scale (C-SSRS). RESULTS: Neither active drug (duloxetine or fluoxetine) separated significantly (p<0.05) from placebo on mean change from baseline to end-point (10 weeks) on the CDRS-R total score. There were no significant differences between the duloxetine or fluoxetine groups compared with placebo on serious AEs (SAEs), total TEAEs, or discontinuation for AE during acute treatment. There were no completed suicides or deaths, and no clinically significant electrocardiogram (ECG) abnormalities observed during the study. One fluoxetine and one duloxetine patient experienced alanine aminotransferase (ALT) three or more times the upper limit of normal, which resolved during the study. A total of 8 (7.1%) duloxetine patients, 7 (6.8%) placebo patients, and 9 (8.0%) fluoxetine patients had worsening of suicidal ideation from baseline during acute treatment. Of the patients with suicidal ideation at baseline, 15/19 (79%) duloxetine, 19/19 (100%) placebo, and 16/19 (84%) fluoxetine had improvement in suicidal ideation at end-point during acute treatment. One duloxetine and two fluoxetine patients had treatment-emergent suicidal behavior during the 36 week study. CONCLUSION: Trial results were inconclusive, as neither the investigational drug (duloxetine) nor the active control (fluoxetine) separated from placebo on the CDRS-R at 10 weeks. No new duloxetine safety signals were identified relative to those seen in adults. Clinical Trial Registry Number: NCT00849901.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 10×
“Only serious AEs (SAEs) elicited through the C-SSRS were recorded as AEs via the study case report forms.”
InfluentialSmall sample inference for fixed effects from restricted maximum likelihood
Kenward, M. G., & Roger, J. H. (1997) · Biometrics · doi:10.2307/2533558 · Cited by 4,552 · cited 1×
“A Kenward–Roger correction (Kenward and Roger 1997) was used to estimate de-nominator degrees of freedom.”
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Sheehan, D. V., Sheehan, K. H., Shytle, R. D., Janavs, J., Bannon, Y., Rogers, J. E., Milo, K. M., Stock, S. L., & Wilkinson, B. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05305whi · Cited by 1,730
Heiligenstein, J. H., Hoog, S. L., Wagner, K. D., Findling, R. L., Galil, N., Kaplan, S., Busner, J., Nilsson, M. E., Brown, E. B., & Jacobson, J. G. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.207 · Cited by 39
Cited by
Locher, C., Koechlin, H., Zion, S. R., Werner, C., Pine, D. S., Kirsch, I., Kessler, R. C., & Kossowsky, J. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2432 · Cited by 360
“We included only continuous outcome data, since dichotomizing continuous scores into categorical outcomedata leads to a loss of information, reduces power, and creates an artificial boundary.(20,21)Wedidnot extract data from improvement scales, suchas theClinicalGlobal Impression-Global ImprovementScale.”
Walkup, J. T. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16091059 · Cited by 112
Zhong, Z., Wang, L., Wen, X., Liu, Y., Fan, Y., & Liu, Z. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s141832 · Cited by 46
“26 Emslie et al 2014 29,a Emslie et al 2014 29 , b Emslie et al 2015 30 Atkinson et al 2014 40 Oslin et al 2003 24”
Ignaszewski, M. J., & Waslick, B. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0174 · Cited by 37
“There were no statistically significant differences in the probability of remission at any time during the 36-week study between patients treated with flexible dosing duloxetine or randomized to fluoxetine (Atkinson et al. 2014).”
InfluentialRohden, A. I., Benchaya, M. C., Camargo, R. S., Moreira, T. D. C., Barros, H. M. T., & Ferigolo, M. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.017 · Cited by 35
Metadata
- Authors
- Atkinson, S. D., Prakash, A., Zhang, Q., Pangallo, B. A., Bangs, M. E., Emslie, G. J., & March, J. S.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2014-05
- Volume
- 24
- Issue
- 4
- Pages
- 180-189
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W4229799006
- Cited by
- 80
- References
- 5
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.